Corange fund stays independent

The Corange-affiliated Global Life Science Limited Partnership said it would not be affected by Roche's planned acquisition of Corange Ltd., announced last week. The fund will remain "very much at arm's length," assured Hanns Peter Wiese, the fund's managing director. Corange chairman Curt Engelhorn started Global Life Science in October with his family's investment of DM25 million (US$14.8 million). Its two other investors -

Read the full 645 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE